Product Details
FAB
- Comprehensive validation - Validated with various antibody drugs.
- Simple and fast operation - No complicated washing steps, significantly reducing time.
- High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
- Accurate and reliable results - High sensitivity with minimal matrix effects.
- High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
- Fast completion - Results in just 1 hour.
Product Specifications
Assay TypeCompetition-TR-FRETReactivityHumanRegulatory StatusRUOAssay Time1 hrSample volume10 μLProduct Overview
The Human TL1A-DR3 inhibition Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screening for inhibitors of human TL1A binding to human DR3 within 0.5-1 hours. It can also be used as a universal detection tool to identify the ability of TL1A to bind to human DR3.
Storage
1. Store the unopened kit at 2-8°C upon receipt.
2. Locate the expiration date on the outer packaging and do not use reagents beyond their expiration date.
3. The opened kit should be stored according to the storage conditions listed in the Components Table. The shelf life of the opened kit is 30 days from the date of opening.
Materials Provided
IDComponentsSizeFRT02-C01Human TL1A Protein Europium-chelate100 tests/500 testsFRT02-C02FA Labeled Human DR3 Protein100 tests/500 testsFRT02-C03Monoclonal Anti-TL1A Antibody, Human IgG120 μg/100 tests 100 μg/500 testsDB-04TR-FRET Sample Dilution Buffer, pH7.450 mL/100 tests & 500 testsDB-05TR-FRET Detection Buffer, pH7.450 mL/100 tests & 500 testsAssay Principles
This Human TL1A-DR3 inhibition kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). Use a mixture of biotinylated human TL1A and Europium-chelate labeled streptavidin as the donor and FA labeled human DR3 protein as the acceptor.
- In the absence of inhibitors for human TL1A binding to human DR3, the donor and acceptor are in close proximity due to the binding of human TL1A and FA-labeled human DR3. Upon excitation with a specific light source, the donor emits a 620 nm signal, which is absorbed by the acceptor, resulting in a 665 nm emission.
- In the presence of inhibitors that block the binding of human TL1A to human DR3, the donor-acceptor interaction is disrupted, preventing FRET from occurring.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-TR-FRET
Please refer to DS document for the assay protocol.

In this TR-FRET assay, Human TL1A Protein Europium-chelate is used as the Donor and FA Labeled Human DR3 Protein is used as the Acceptor. An inhibition Assay was performed to evaluate the interaction between human TL1A and human DR3 using Monoclonal Anti-TL1A Antibody, Human IgG1 resulting in a typical IC50 of 3.024 nM (QC tested).

The kit is suitable for the detection and characterization of TL1A/DR3 inhibitors. It was shown that the two anti-TL1A antibodies (Afimkibart& Tulisokibart) disrupted the interaction, with an IC50 of 2.890 & 8.198 nM.
Customer Reviews Writing Reviews

Recent Advances
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521



















